Orphazyme A's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Orphazyme A (ORPH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Orphazyme A vs Its Competitors
- TTM: Trailing 12-month revenue of 36M vs 1M combined for tracked competitors (97.7% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-36.4% annualized vs trailing 12 months), vs accelerating (+168.8%) for its tracked peer group.
- Profitability: Its -1,731.1% net margin compares with -477.2% for the peer group.
- Peer revenue share: Orphazyme A accounted for 90.8% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ORPH Sales vs. its Competitors, Q4 2021
With a net margin of -1,731.11 %, Orphazyme A reported lower profitability than its competitors (-477.24 %).
Orphazyme A generated 90.78 % of the combined sales of its peer group.
Orphazyme A vs. its Competitors, Q4 2021
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Orphazyme A and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Orphazyme A | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Orphazyme A's competitor groups requires a Commercial License.
Orphazyme A's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Orphazyme A | - | - | - | - |
| Competitors combined (1) | - | |||
| High-Confidence Competitors (1) | - | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ORPH Stock Performance relative to its Competitors
ORPH Stock Performance relative to High-Confidence Competitors
Publicly Traded Peers of Orphazyme A
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Orphazyme A | 30.38 | 36.19 |
| Cyclo Therapeutics Inc | 20.70 | 0.87 |
| SUBTOTAL | 51.09 | 37.06 |
Sources: Orphazyme A's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Orphazyme A versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Orphazyme A's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Ladrx Corporation | Named by the company | 85% |
| Cyclo Therapeutics Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Orphazyme A's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Orphazyme A's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Orphazyme A | 30 | - | - |
| Cyclo Therapeutics Inc | 21 | 30,025 | -457,358 |
| PEERS TOTAL | 21 | 30,025 | -457,358 |
Orphazyme A's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-36.4% annualized vs trailing 12 months).
Opportunities
- A meaningful share of tracked competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Orphazyme A's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Orphazyme A | 0.79 | 1.23 | 3.58 |
| Cyclo Therapeutics Inc | 0.33 | 0.61 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Orphazyme A's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Orphazyme A | Q4 2021 | - | - |
| Cyclo Therapeutics Inc | Q3 2024 | -52.8 % | - |
| PEERS TOTAL | +7,251.9 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Orphazyme A's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Orphazyme A | Q4 2021 | - | -96.1 % |
| Cyclo Therapeutics Inc | Q3 2024 | - | - |
Orphazyme A's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Orphazyme A | - | - | - |
| Cyclo Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Orphazyme A's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Orphazyme A | - | 0.84 |
| Cyclo Therapeutics Inc | - | 23.78 |
| PEERS AVERAGE | - | 1.38 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.